Optimism On ICDs: St. Jude And Boston Scientific Exceed Expectations
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical reported strong cardiac rhythm management results in the second quarter and said it picked up market share, but struggling competitor Boston Scientific refused to recoil, announcing U.S. ICD sales losses that were about half what was expected
You may also be interested in...
Boston Scientific Tries To Climb Back Up From ICD Market Share Spill
Boston Scientific is banking on intense communication with physicians and new product launches to eventually pull its ICD business back to its pre-sales-suspension standing, but the firm acknowledges that it will be playing catch-up for the foreseeable future
Boston Scientific Resumes Most, Not All, Implantable Defibrillator Shipments
Boston Scientific resumed shipments of virtually all of its implantable defibrillators April 15 following retrospective clearance by FDA of two manufacturing changes
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.